IP Library Granted Patent US 9,079,847
Granted Patent B2
US 9,079,847 · App. 13/574,634 · Granted Jul 14, 2015

Process for preparing and purifying fatty acids

Inventors: Adam Kelliher (London, GB); Angus Morrison (Isle of Lewis, GB); Phil Knowles (Cumbria, GB)
Assignee: BASF PHARMA (CALLANISH) LIMITED
C07C51/487C07C51/38C07C51/41C07C51/412C07C51/42C07C51/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,079,847
App. No.
13/574,634
Granted
Jul 14, 2015
Kind
B2
Abstract

There is provided a process for purifying a fatty acid, which process comprises reacting a fatty acid with a lithium salt in a first solution and under conditions to allow formation of a precipitate of a lithium salt of the fatty acid; isolating the precipitate; dissolving the precipitate in a second solution followed by separation of the organic and aqueous layers so formed; and evaporating the organic layer to isolate the purified fatty acid. There is also provided a process for increasing the length of a fatty acid, and the use of a lithium salt to purify a fatty acid.

Claims (31)

1. A process for purifying a fatty acid which has 1 to 6 centers of unconjugated unsaturation, which process comprises:

(a) reacting a fatty acid with a lithium salt in a first solution and under conditions to allow formation of a precipitate of a lithium salt of the fatty acid;

(b) isolating the precipitate;

(c) dissolving the precipitate in a second solution which is capable of generating two immiscible layers upon dissolution of the precipitate, the two immiscible layers being an organic layer and an aqueous acidic layer;

(d) separating the two immiscible layers formed upon dissolution of the precipitate; and

(e) evaporating the organic layer to isolate the purified fatty acid,

wherein the process does not involve separating fatty acids from one another.

2. A process according to claim 1 wherein the fatty acid is selected from the group consisting of dihomo-gamma-linolenic acid (DGLA), eicosadienoic acid, docosapentaenoic acid (DPA), eicosatetraenoic acid (ETA) and eicosatrienoic acid.

3. A process according to claim 1 wherein the fatty acid is a C 14-24 fatty acid.

4. A process according to claim 1 wherein the lithium salt is lithium hydroxide.

5. A process for preparing a fatty acid which has 1 to 6 centers of unconjugated unsaturation, which process comprises:

(a) decarboxylating a malonic acid derivative of formula R—CH 2 CH(CO 2 H) 2 , wherein R is a fatty acid residue which contains from 1 to 6 centers of unconjugated unsaturation, to form a fatty acid of formula RCH 2 CH 2 CO 2 H;

(b) subjecting the fatty acid thus prepared to a process for purifying a fatty acid as defined in claim 1 .

6. A process for extending the length of a fatty acid which has 1 to 6 centers of unconjugated unsaturation, which process comprises:

(a) reducing a fatty acid of formula R—CO 2 H or a fatty acid ester of formula R—CO 2 R 1 , wherein R is a fatty acid residue which contains from 1 to 6 centers of unconjugated unsaturation and R 1 is a C 1-6 alkyl group, to an alcohol of formula R—CH 2 OH;

(b) sulfonating the alcohol to form a sulfonate of formula R—CH 2 OSO 2 R 2 , wherein R 2 is a C 1-6 alkyl or C 6-10 aryl group;

(c) reacting the sulfonate with a malonate ester derivative and hydrolysing the resulting product to form a malonic acid derivative of formula R—CH 2 CH(CO 2 H) 2 ;

(d) decarboxylating the malonic acid derivative to form a fatty acid of formula R—CH 2 CH 2 CO 2 H; and

(e) subjecting the fatty acid thus prepared to a process for purifying a fatty acid as defined in claim 1 .

7. A process according to claim 6 wherein R is a fatty acid residue comprising from 14 to 22 carbon atoms.

8. A process according to claim 7 wherein R comprises from 18 to 20 carbon atoms.

9. A process according to claim 6 wherein R comprises 2 to 6 unconjugated olefinic groups.

10. A process according to claim 6 wherein R is selected from the group consisting of ω-3 and ω-6 fatty acid residues.

11. A process according to claim 6 wherein R is selected from the group consisting of a C 17 H 29 residue from gamma-linolenic acid, a C 19 H 29 residue from eicosapentaenoic acid, a C 17 H 27 residue from stearidonic acid, a C 17 H 31 residue from linoleic acid and a C 17 H 29 residue from alpha-linolenic acid.

12. A process according to claim 6 wherein the reduction in step (a) is carried out with a solution of lithium aluminium hydride.

13. A process according to claim 6 wherein the malonic acid derivative of formula R—CH 2 CH(CO 2 H) 2 is used directly in the decarboxylation of step (d) without purification and/or without crystallisation.

14. A process according to claim 5 wherein R is a fatty acid residue comprising from 14 to 22 carbon atoms.

15. A process according to claim 14 wherein R comprises from 18 to 20 carbon atoms.

16. A process according to claim 5 wherein R comprises 2 to 6 unconjugated olefinic groups.

17. A process according to claim 5 wherein R is selected from the group consisting of ω-3 and ω-6 fatty acid residues.

18. A process according to claim 5 wherein R is chosen from the group consisting of a C 17 H 29 — residue from gamma-linolenic acid, a C 19 H 29 — residue from eicosapentaenoic acid, a C 17 H 27 — residue from stearidonic acid, a C 17 H 31 — residue from linoleic acid and a C 17 H 29 — residue from alpha-linolenic acid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2020
From: BASF PHARMA (CALLANISH) LIMITED
To: DS BIOPHARMA LIMITED
Reel/Frame 054720/0676 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2012
From: KELLIHER, ADAM; MORRISON, ANGUS; KNOWLES, PHIL
To: BASF PHARMA (CALLANISH) LIMITED
Reel/Frame 029005/0196 →
Priority Claims (1)
GB 1001345.6 · Jan 27, 2010 · national
Continuity (1)
Related Publication 20130150602A1 · Jun 13, 2013